These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 1976128)

  • 1. Therapeutic applications of drugs acting on peripheral dopamine receptors.
    Horn PT; Murphy MB
    J Clin Pharmacol; 1990 Aug; 30(8):674-9. PubMed ID: 1976128
    [No Abstract]   [Full Text] [Related]  

  • 2. Pharmacological bases for the use of dopamine and related drugs in the treatment of congestive heart failure.
    Goldberg LI
    J Cardiovasc Pharmacol; 1989; 14 Suppl 8():S21-8. PubMed ID: 2483439
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiovascular and renal action of dopaminergic prodrugs.
    Casagrande C; Merlo L; Ferrini R; Miragoli G; Semeraro C
    J Cardiovasc Pharmacol; 1989; 14 Suppl 8():S40-59. PubMed ID: 2483441
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of dopamine receptors in the treatment of congestive heart failure.
    Goldberg LI
    J Cardiovasc Pharmacol; 1989; 14 Suppl 5():S19-27. PubMed ID: 2478806
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of dopaminergic agents and the dopamine receptor in treatment for CHF.
    Carey RA; Jacob L
    J Clin Pharmacol; 1989 Mar; 29(3):207-11. PubMed ID: 2566626
    [No Abstract]   [Full Text] [Related]  

  • 6. Comparison of cardiorenal and emetic effects of dopamine prodrugs docarpamine (TA-870) and levodopa in dogs.
    Nishiyama S; Kanno K; Yamaguchi I
    J Pharmacobiodyn; 1991 Mar; 14(3):120-5. PubMed ID: 1679131
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Mechanism of action of ibopamine: pharmacological effects of epinine and other metabolites].
    Ferrini R; Merlo L; Miragoli G
    Cardiologia; 1988 Jan; 33(1):49-53. PubMed ID: 2835159
    [No Abstract]   [Full Text] [Related]  

  • 8. [New inotropic agents in the treatment of congestive heart failure].
    Freitas M
    Rev Port Cardiol; 1993 Nov; 12 Suppl 4():19-28, 7-8. PubMed ID: 7904458
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dopamine: receptors and clinical applications.
    Goldberg LI
    Clin Physiol Biochem; 1985; 3(2-3):120-6. PubMed ID: 3159532
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neurotoxin-related research: from the laboratory to the clinic.
    Iversen L; Foster AC; Hill RG; Iversen SD; Kemp JA; Leeson PD; Rupniak NM; Saywell K; Tricklebank MD; Williams BJ
    Ann N Y Acad Sci; 1992 May; 648():207-18. PubMed ID: 1353328
    [No Abstract]   [Full Text] [Related]  

  • 11. [Ibopamine--pharmacologic principles].
    Borchard U
    Z Kardiol; 1991; 80 Suppl 8():63-6. PubMed ID: 1686693
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Possible applications for dopaminergic agents following traumatic brain injury: part 1.
    Zafonte RD; Lexell J; Cullen N
    J Head Trauma Rehabil; 2000 Oct; 15(5):1179-82. PubMed ID: 10970937
    [No Abstract]   [Full Text] [Related]  

  • 13. Pharmacotherapeutic profile of ibopamine in heart failure.
    Taylor SH
    J Cardiovasc Pharmacol; 1989; 14 Suppl 8():S118-23. PubMed ID: 2483437
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical use of dopamine receptor agonists.
    Murphy MB
    Proc West Pharmacol Soc; 1990; 33():31-5. PubMed ID: 1980363
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Dopamine and dopaminergic drugs as therapeutic agents in heart failure].
    van Zwieten PA
    Ned Tijdschr Geneeskd; 1990 Nov; 134(47):2281-4. PubMed ID: 1979426
    [No Abstract]   [Full Text] [Related]  

  • 16. [Dysthymic disorders and dopaminergic drugs].
    Schmitt L; Olivier F; Fournié-DeJean I
    Encephale; 1992 Dec; 18 Spec No 5():755-9. PubMed ID: 1364157
    [No Abstract]   [Full Text] [Related]  

  • 17. [Sepsis].
    Spoto S; Navajas Martinez MF; Costantino S
    Clin Ter; 2002; 153(6):439-40. PubMed ID: 12645402
    [No Abstract]   [Full Text] [Related]  

  • 18. Current literature questions the routine use of low-dose dopamine.
    Abay MC; Reyes JD; Everts K; Wisser J
    AANA J; 2007 Feb; 75(1):57-63. PubMed ID: 17304785
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Current developments in the pharmacology of the dopaminergic receptors. III].
    Nechifor M; Lucaci L
    Rev Med Chir Soc Med Nat Iasi; 1989; 93(3):510, 516, 566. PubMed ID: 2576889
    [No Abstract]   [Full Text] [Related]  

  • 20. Physiology and pharmacology of dopamine D2-receptors: their implications in dopamine-substitute therapy for Parkinson's disease.
    Mercuri NB; Calabresi P; Bernardi G
    Neurology; 1989 Aug; 39(8):1106-8. PubMed ID: 2569697
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.